Navigation Links
VaxGen Files 2006 Financial Statements and Provides Cash Update
Date:8/30/2007

SOUTH SAN FRANCISCO, Calif., Aug. 30 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN) announced today that it has filed with the Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the year ended December 31, 2006 and Quarterly Reports on Form 10-Q for the first three quarters of 2006. The reports can be found at the link titled "SEC Filings" in the Investor Relations section of VaxGen's web site at http://www.vaxgen.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

The only financial statements the company has outstanding before it regains compliance with its SEC financial reporting obligations are the Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2007, both of which are under review by VaxGen and its independent auditors. Once VaxGen is current with its financial statements, the company intends to apply for listing on a national stock exchange.

VaxGen's estimated cash, cash equivalents and short-term investments totaled $85.7 million as of the end of the company's most recent quarter on June 30, 2007.

VaxGen, Inc. is a biopharmaceutical company located in South San Francisco. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the anticipated filing of the company's outstanding quarterly reports and its application for listing of its common stock. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE VaxGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. PCR Polymerases Application Profiles
2. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
3. Obtaining a contour map from multifiles or 3D data in DataMax
4. Successful stabilization of gene expression profiles
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Third Wave files countersuit vs. Digene in patent case
7. TomoTherapy files registration statement for IPO
8. Merge files financial reports by market opening
9. The Why Files celebrates decade of science exploration
10. Third Wave files patent suits against Digene, Chiron and Bayer
11. New Web virus could lead to lost files, extortion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Mass. , March 29, 2017 /PRNewswire/ ... in applying mechanistic modeling to drug research ... their collaboration with Zymeworks Inc. for quantitative ... conjugate therapeutics intended for the treatment of ... supported Zymeworks previously for GLP toxicology studies ...
(Date:3/29/2017)... ... March 29, 2017 , ... On the heels of the ... Colpitts Clinical Trial Travel has announced that it will manage travel services for its ... the first in the United States and Europe to offer travel management services specifically ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... today that it is exhibiting in booth 513 at the Association of Community ... DC Downtown Hotel, March 29-31. , CANCERSCAPE unites key stakeholders from leading ...
(Date:3/29/2017)... 2017 Research and Markets has announced the ... - Industry Forecast to 2025" report to their offering. ... The Global Agricultural ... 7.8% over the next decade to reach approximately $825.4 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology Technology:
(Date:3/9/2017)... Australia , March 9, 2017 ... the prestigious World Lung Imaging Workshop at the University ... , was invited to deliver the latest data to ... globally recognised event brings together leaders at the forefront ... developments in lung imaging. "The quality ...
(Date:3/6/2017)... Calif. , March 6, 2017 ... and sales technology, today announced Predictive Sales Coach ... for infusing actionable sales intelligence into Salesforce. This ... automatically enable their sales organizations with deep knowledge ... that allow for intelligent engagement. Predictive Sales Coach ...
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
Breaking Biology News(10 mins):